IN8bio Presents Preclinical Data Showing Non-Signaling CAR Platform Targets Cancer Cells While Preserving Healthy Tissue

~ Next-generation gamma-delta T cell CAR technology targets tumors while sparing healthy tissue. ~ Greater than 15x difference in killing between tumor cells and healthy B cells with the non-signaling gamma-delta CAR-T platform (nsCAR) utilizing the validated target of CD19 as proof-of-concept. ~ Leveraging the unique properties of gamma-delta T cells supports the potential to broaden the utilization of CAR technology for previously “undruggable” solid- and liquid-tumor targets.

Thank you for visiting Tailwinds Research. We are pleased to offer free research on select small and micro cap companies. It is free to join and we hope you’ll take the time to do so.

To create an account please click on this link.

If you already have an account, please log in here.


Please enter your comment!
Please enter your name here